Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1

Vaccine

Volumn 28, Issue 41, 2010, Pages 6749-6756

  Sealy, R ^a   Jones, B G ^a   Surman, S L ^a   Hurwitz, J L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibody forming cells; HPIV 1 protection; Nasal associated lymphoid tissue; Parainfluenza virus; Upper respiratory tract

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PARAINFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ANTIBODY RESPONSE; ARTICLE; BONE MARROW; CONTROLLED STUDY; IMMUNOREACTIVITY; LYMPHOID TISSUE; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; RAT; SENDAI VIRUS; SPLEEN; VACCINE PRODUCTION; VIRUS RESISTANCE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIBODY-PRODUCING CELLS; BONE MARROW CELLS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LUNG; NOSE; PARAINFLUENZA VIRUS 1, HUMAN; RESPIROVIRUS INFECTIONS; SENDAI VIRUS; SIGMODONTINAE;

EID: 77956461346     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.068     Document Type: Article

References (72)

1. Henderson F.W. Pulmonary infections with respiratory syncytial virus and the parainfluenza viruses. Semin Respir Infect 1987, 2(June (2)):112-121.
2. Henrickson K.J., Kuhn S.M., Savatski L.L. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis 1994, 18:770-779.
3. Henrickson K.J., Hoover S., Kehl K.S., Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 2004, 23(January (Suppl. 1)):S11-S18.
4. Heilman C.A. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990, 161(March (3)):402-406.
5. Ishida N., Homma M. Sendai virus. Adv Virus Res 1978, 23:349-383.
6. Tai F.-H., Chiu S., Ma C.-C. Seroepidemiologic studies of Sendai virus infection in Taiwan. Taiwan I Hsueh Hui Tsa Chih 1967, 66:312-318.
7. Stark J.E., Heath R.B. The development of antibodies against Sendai virus in childhood. Arch Gesamte Virusforsch 1967, 20:438-444.
8. Chanock R.M., Murphy B.R., Collins P.L. Parainfluenza viruses. Fields Virology 2001, 1341-1379. Lippincott Williams and Wilkins, Philadelphia, PA. 4th ed. D.M. Knipe, P.M. Howley (Eds.).
9. Lyn D., Gill D.S., Scroggs R.A., Portner A. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants. J Gen Virol 1991, 72:983-987.
10. Gorman W.L., Gill D.S., Scroggs R.A., Portner A. The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and sendai virus have high structure-function similarity with limited antigenic cross-reactivity. Virology 1990, 175:211-223.
11. Smith F.S., Portner A., Leggiadro R.J., Turner E.V., Hurwitz J.L. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology 1994, 205(December (2)):453-461.
12. Dave V.P., Allan J.E., Slobod K.S., Smith S.F., Ryan K., Powell U., et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology 1994, 199:376-383.
13. Hurwitz J.L., Soike K.F., Sangster M.Y., Portner A., Sealy R.E., Dawson D.H., et al. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 1997, 15:533-540.
14. Skiadopoulos M.H., Surman S.R., Riggs J.M., Elkins W.R., St C.M., Nishio M., et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 2002, 297(May (1)):153-160.
15. Wyke Coelingh K.L., Winter C.C., Tierney E.L., London W.T., Murphy B.R. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 1988, 157(April (4)):655-662.
16. Greenberg D.P., Walker R.E., Lee M.S., Reisinger K.S., Ward J.I., Yogev R., et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 2005, 191(April (7)):1116-1122.
17. Takimoto T., Hurwitz J.L., Coleclough C., Prouser C., Krishnamurthy S., Zhan X., et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol 2004, 78(June (11)):6043-6047.
18. Takimoto T., Hurwitz J.L., Zhan X., Krishnamurthy S., Prouser C., Brown B., et al. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol 2005, 18(2):255-266.
19. Zhan X., Hurwitz J.L., Krishnamurthy S., Takimoto T., Boyd K., Scroggs R.A., et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine 2007, 25(December (52)):8782-8793.
20. Zhan X., Slobod K.S., Krishnamurthy S., Luque L.E., Takimoto T., Jones B., et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine 2008, 26(June (27-28)):3480-3488.
21. Voges B., Vallbracht S., Zimmer G., Bossow S., Neubert W.J., Richter K., et al. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. Cell Immunol 2007, 247(June (2)):85-94.
22. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., Allison K., Brown B., Scroggs R.A., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004, 22(August (23/24)):3182-3186.
23. Jones B., Zhan X., Mishin V., Slobod K.S., Surman S., Russell C.J., et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009, 27(March (12)):1848-1857.
24. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 2001, 51(September (1-3)):21-42.
25. Asanuma H., Thompson A.H., Iwasaki T., Sato Y., Inaba Y., Aizawa C., et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods 1997, 202(March (2)):123-131.
26. Koff R.S. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 2002, 20(November (31-32)):3695-3701.
27. Zuckerman J.N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006, 78(February (2)):169-177.
28. Hyland L., Sangster M., Sealy R., Coleclough C. Respiratory virus infection of mice provokes a permanent humoral immune response. J Virol 1994, 68:6083-6086.
29. Slifka M.K., Matloubian M., Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 1995, 69(March (3)):1895-1902.
30. Murphy K., Travers P., Walport M. Janeway's Immunobiology 2008, Garland Science, New York, NY. 7 ed.
31. Slifka M.K., Antia R., Whitmire J.K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8(March (3)):363-372.
32. Siber G.R., Leombruno D., Leszczynski J., McIver J., Bodkin D., Gonin R., et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994, 169(June (6)):1368-1373.
33. Sami I.R., Piazza F.M., Johnson S.A., Darnell M.E., Ottolini M.G., Hemming V.G., et al. Systemic immunoprophylaxis of nasal respiratory syncytial virus infection in cotton rats. J Infect Dis 1995, 171(February (2)):440-443.
34. Renegar K.B., Small P.A. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 1991, 146(March (6)):1972-1978.
35. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008, 82(March (5)):2040-2055.
36. Prince G.A., Hemming V.G., Horswood R.L., Chanock R.M. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985, 3:193-206.
37. Prince G.A., Horswood R.L., Chanock R.M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985, 55(September (3)):517-520.
38. DeVincenzo J.P. Factors predicting childhood respiratory syncytial virus severity: what they indicate about pathogenesis. Pediatr Infect Dis J 2005, 24(November (Suppl. 11)):S177-S183. [discussion].
39. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176(November (5)):1215-1224.
40. Sangster M.Y., Riberdy J.M., Gonzalez M., Topham D.J., Baumgarth N., Doherty P.C. An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions. J Exp Med 2003, 198(October (7)):1011-1021.
41. Sealy R., Surman S., Hurwitz J.L., Coleclough C. Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens. Immunology 2003, 108(April (4)):431-439.
42. Coleclough C., Sealy R., Surman S., Marshall D.R., Hurwitz J.L. Respiratory vaccination of mice against influenza virus: dissection of T- and B-cell priming functions. Scand J Immunol 2005, 62(July (Suppl. 1)):73-83.
43. Mora J.R., Von Andrian U.H. Differentiation and homing of IgA-secreting cells. Mucosal Immunol 2008, 1(March (2)):96-109.
44. Mora J.R., Von Andrian U.H. Role of retinoic acid in the imprinting of gut-homing IgA-secreting cells. Semin Immunol 2009, 21(February (1)):28-35.
45. Mora J.R., Iwata M., Eksteen B., Song S.Y., Junt T., Senman B., et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006, 314(November (5802)):1157-1160.
46. Endsley M.A., Njongmeta L.M., Shell E., Ryan M.W., Indrikovs A.J., Ulualp S., et al. Human IgA-inducing protein from dendritic cells induces IgA production by naive IgD+ B cells. J Immunol 2009, 182(February (4)):1854-1859.
47. Kawanishi H., Saltzman L.E., Strober W. Mechanisms regulating IgA class-specific immunoglobulin production in murine gut-associated lymphoid tissues. I. T cells derived from Peyer's patches that switch sIgM B cells to sIgA B cells in vitro. J Exp Med 1983, 157:433.
48. Ehrhardt R.O., Strober W., Harriman G.R. Effect of transforming growth factor (TGF)-beta 1 on IgA isotype expression. TGF-beta 1 induces a small increase in sIgA+ B cells regardless of the method of B cell activation. J Immunol 1992, 148(June (12)):3830-3836.
49. Iwasaki A. Mucosal dendritic cells. Annu Rev Immunol 2007, 25:381-418.
50. Gallichan W.S., Rosenthal K.L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995, 13(November (16)):1589-1595.
51. Mora J.R., Bono M.R., Manjunath N., Weninger W., Cavanagh L.L., Rosemblatt M., et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003, 424(July (6944)):88-93.
52. Kiyono H., Fukuyama S. NALT versus Peyer's patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4(September (9)):699-710.
53. Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009, 70(December (6)):505-515.
54. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25(July (30)):5467-5484.
55. Hiroi T., Yanagita M., Iijima H., Iwatani K., Yoshida T., Takatsu K., et al. Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. J Immunol 1999, 162(January (2)):821-828.
56. Kunkel E.J., Kim C.H., Lazarus N.H., Vierra M.A., Soler D., Bowman E.P., et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 2003, 111(April (7)):1001-1010.
57. Lazarus N.H., Kunkel E.J., Johnston B., Wilson E., Youngman K.R., Butcher E.C. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 2003, 170(April (7)):3799-3805.
58. Sabirov A., Metzger D.W. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine 2008, 26(March (12)):1566-1576.
59. Wiley J.A., Tighe M.P., Harmsen A.G. Upper respiratory tract resistance to influenza infection is not prevented by the absence of either nasal-associated lymphoid tissue or cervical lymph nodes. J Immunol 2005, 175(September (5)):3186-3196.
60. Ying X., Chan K., Shenoy P., Hill M., Ruddle N.H. Lymphotoxin plays a crucial role in the development and function of nasal-associated lymphoid tissue through regulation of chemokines and peripheral node addressin. Am J Pathol 2005, 166(January (1)):135-146.
61. Liang B., Hyland L., Hou S. Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J Virol 2001, 75(June (11)):5416-5420.
62. Singleton R., Etchart N., Hou S., Hyland L. Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol 2003, 77(November (21)):11303-11311.
63. Joo H.M., He Y., Sangster M.Y. Broad dispersion and lung localization of virus-specific memory B cells induced by influenza pneumonia. Proc Natl Acad Sci USA 2008, 105(March (9)):3485-3490.
64. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171(November (10)):4969-4973.
65. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004, 23(February (2)):106-110.
66. Slifka M.K., Ahmed R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol 1996, 4(October (10)):394-400.
67. Gray D. Immunological memory: a function of antigen persistence. Trends Microbiol 1993, 1(May (2)):39-41.
68. Sikkel M.B., Quint J.K., Mallia P., Wedzicha J.A., Johnston S.L. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J 2008, 27(October (Suppl. 10)):S63-S70.
69. Ahuja A., Anderson S.M., Khalil A., Shlomchik M.J. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci USA 2008, 105(March (12)):4802-4807.
70. Maruyama M., Lam K.P., Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 2000, 407(October (6804)):636-642.
71. Maruyama M., Lam K.P., Rajewsky K. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 1991, 88(March (6)):2283-2287.
72. Kast W.M., Roux L., Curren J., Blom H.J., Voordouw A.C., Meloen R.H., et al. A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein. J Virol 2007, 81(November (22)):12535-12542.